XML 48 R35.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Revenue (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Revenue from Contract with Customer [Abstract] |
Schedule of Revenue | Disaggregation of total revenues by nature is as follows:
| Year Ended December 31, |  |  |  |
(in thousands) | 2024 |  | 2023 |  | 2022 |  |  |  |  |  |  |
Product sales, net | $ | 319,196 |  |  | $ | 82,526 |  |  | $ | 15,600 |  |  |  |  |  |  |  |  |
Product supply revenue | 11,649 |  |  | 6,121 |  |  | 1,527 |  |  |  |  |  |  |  |  |
Licensing revenue | 78 |  |  | 35,809 |  |  | 35,031 |  |  |  |  |  |  |  |  |
Non-cash royalty revenue related to the sale of future royalties | 2,692 |  |  | — |  |  | — |  |  |  |  |  |  |  |  |
Total revenues | $ | 333,615 |  |  | $ | 124,456 |  |  | $ | 52,158 |  |  |  |  |  |  |  |  |
Total product sales, net was as follows:
| Year Ended December 31, |  |  |  |
(in thousands) | 2024 |  | 2023 |  | 2022 |  |  |  |  |  |  |
Product sales, net |  |  |  |  |  |  |  |  |  |  |  |  |
IBSRELA | $ | 158,286 |  |  | $ | 80,062 |  |  | $ | 15,600 |  |  |  |  |  |  |  |  |
XPHOZAH | 160,910 |  |  | 2,464 |  |  | — |  |  |  |  |  |  |  |  |
Total product sales, net | $ | 319,196 |  |  | $ | 82,526 |  |  | $ | 15,600 |  |  |  |  |  |  |  |  |
The following table summarizes total revenue by collaboration partner:
| Year Ended December 31,
(in thousands) | 2024 |  | 2023 |  | 2022
Licensing revenue |  |  |  |  |
Kyowa Kirin | $ | — |  |  | $ | 30,000 |  |  | $ | 35,000 |
Fosun Pharma | — |  |  | 5,000 |  |  | — |
METiS | — |  |  | 750 |  |  | — |
Knight | 78 |  |  | 59 |  |  | 31 |
Total licensing revenue | $ | 78 |  |  | $ | 35,809 |  |  | $ | 35,031 |
Product supply revenue |  |  |  |  |
Kyowa Kirin | 11,649 |  |  | 6,092 |  |  | 1,518 |
Fosun Pharma | — |  |  | 29 |  |  | 9 |
Total supply revenue | $ | 11,649 |  |  | $ | 6,121 |  |  | $ | 1,527 |
Non-cash royalty revenue related to the sale of future royalties |  |  |  |  |
Kyowa Kirin | $ | 2,692 |  |  | $ | — |  |  | $ | — |
Schedule of Gross To Net Adjustments of Revenue | The activities and ending reserve balances for each significant category of GTN adjustments on product sales, net, which constitute variable consideration, were as follows:
(in thousands) | Discounts and chargebacks |  | Rebates, wholesaler and GPO fees |  | Copay assistance and returns |  | Total
Balance as of December 31, 2022 | $ | 142 |  |  | $ | 1,444 |  |  | $ | 1,258 |  |  | $ | 2,844 |
Provisions | 5,341 |  |  | 15,365 |  |  | 10,629 |  |  | 31,335 |
Credits/payments | (5,005) |  |  | (12,575) |  |  | (7,971) |  |  | (25,551) |
Balance as of December 31, 2023 | 478 |  |  | 4,234 |  |  | 3,916 |  |  | 8,628 |
Provisions | 15,099 |  |  | 65,833 |  |  | 28,925 |  |  | 109,857 |
Credits/payments | (13,934) |  |  | (55,592) |  |  | (21,671) |  |  | (91,197) |
Balance as of December 31, 2024 | $ | 1,643 |  |  | $ | 14,475 |  |  | $ | 11,170 |  |  | $ | 27,288 |
Schedule of Revenue by Geographic Areas | A summary of our revenues by geographic area is as follows:
| Year Ended December 31,
(in thousands) | 2024 |  | 2023 |  | 2022
United States(1) | $ | 319,196 |  |  | $ | 83,276 |  |  | $ | 15,600 |
International |  |  |  |  |
Asia Pacific(2) | 14,341 |  |  | 41,121 |  |  | 36,527 |
North America(3) | 78 |  |  | 59 |  |  | 31 |
Total revenues | $ | 333,615 |  |  | $ | 124,456 |  |  | $ | 52,158 |
(1)Revenues from the United States are primarily comprised of amounts earned from sales of IBSRELA and XPHOZAH, as well as the upfront license fee from the METiS Agreement. (2)Revenues from Asia Pacific are primarily comprised of amounts earned in accordance with the Kyowa Kirin Agreement and the Fosun Agreement. (3)Revenues from North America are comprised of amounts earned from Canada in accordance with the Knight Agreement.
Schedule of Revenue from Customers as a Percentage of Total Product Revenue, Net | Gross product sales from Customers and revenues from collaboration partners, each accounting for more than 10% of total revenues, were as follows:
| Year Ended December 31,
| 2024 |  | 2023 |  | 2022
Customers |  |  |  |  |
BioRidge Pharma, LLC | 75.4 | % |  | 24.0 | % |  | 3.2 | %
Cencora | 16.4 | % |  | 19.1 | % |  | 11.1 | %
Cardinal Health | 14.5 | % |  | 19.8 | % |  | 9.6 | %
McKesson Corporation | 14.1 | % |  | 15.7 | % |  | 8.9 | %
Collaboration partners |  |  |  |  |
Kyowa Kirin | 4.3 | % |  | 29.0 | % |  | 70.0 | %

X
- Definition Schedule Of Gross To Net Sales Adjustments Of Revenue + References No definition available. + Details
Name: | ardx_ScheduleOfGrossToNetSalesAdjustmentsOfRevenueTableTextBlock
Namespace Prefix: | ardx_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-21 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration